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Abstract
Pre-exposure prophylaxis (PrEP) has the potential to significantly reduce HIV incidence among men who have
sex with men (MSM) in the United States. However, the extent to which suboptimal PrEP adherence and re-
tention in care may limit successful implementation is unknown. An agent-based model was used to represent the
entire population of MSM in Rhode Island from 2013 to 2017. The impact of potential interventions to improve
PrEP adherence and retention in care on HIV transmission was evaluated. Demographics, behaviors, and PrEP
adherence and retention in care rates were based on local clinical data. We assumed that 20% of HIV-negative
MSM had ever taken PrEP. The primary outcome was HIV incidence over the 5-year period. The model included
23,815 MSM with an estimated 4.1% HIV prevalence based on local surveillance data. An estimated 173.1 new
infections occurred over 5 years [95% simulation interval (SI): 171.5–174.7], including 29.1 new infections
among individuals who had ever initiated PrEP (95% SI: 28.6–29.7). Interventions that improved retention in
PrEP care by an odds of 5.0 compared with the base case maximized reductions in HIV incidence among MSM
who had ever initiated PrEP by 37.5%. Interventions focusing on improving PrEP adherence had little to no
effect on HIV incidence, regardless of intervention efficacy. Retention in care is a critical component of the PrEP
care continuum. Interventions that improve retention in PrEP care may lead to greater reductions in population-
level HIV incidence compared with interventions focused exclusively on adherence.
Keywords: HIV, prevention, PrEP, MSM, agent-based modeling
Introduction
Men who have sex with men (MSM) continue to bedisproportionately impacted by HIV in the United
States, with a 1 in 11 lifetime risk of HIV infection.1 Pre-
exposure prophylaxis (PrEP) is highly efficacious in pre-
venting HIV acquisition and has the potential to help achieve
the goals of the National HIV/AIDS Strategy.2,3 Defining a
PrEP care continuum is important to identify gaps in im-
plementation and includes PrEP awareness, linkage to care,
initiation, adherence, and retention in care.4 Previous studies
have demonstrated challenges in the initial stages of the PrEP
care continuum.4 A previous agent-based model (ABM) of
HIV transmission among MSM in Rhode Island found that
substantial increases in uptake are needed to decrease HIV
incidence in this setting,5 with other modeling studies reach-
ing similar conclusions.6,7 However, less is known about ad-
herence and retention in PrEP care in real-world settings and
their impact on population-level HIV incidence. Previous
studies have demonstrated suboptimal adherence and low
retention in care that may significantly impact the effective-
ness of PrEP at the population level.8–10
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Adherence to daily pill taking is essential for conferring
individual-level protection from HIV infection.11 Several
studies have demonstrated that poor adherence to PrEP has
the potential to considerably diminish estimates of efficacy
in randomized controlled trials.8,9 Several measurements are
often used to characterize adherence, including measures
based on self-report, pill counts, and serum drug levels,
leading to challenges in assessing adherence and strategies to
improve it.12 Adherence to daily pill taking is heavily im-
pacted by several barriers, including anticipated and enacted
stigma, where individuals do not want to be seen taking PrEP
because of concerns about being perceived be promiscuous
and/or living with HIV infection.13
The reasons for PrEP discontinuation are much less un-
derstood than those for nonadherence to PrEP. Reductions in
perceived risk for HIV infection because of changes in sexual
behaviors are a common reason for discontinuation. In
qualitative interviews with MSM in Rhode Island, Underhill
et al.14 found that many individuals report temporal shifts in
risk behavior, perceived risk of HIV infection, and willingness
to use PrEP. In some periods of increased numbers of sexual
partners, for example, perceived risk of HIV infection is higher,
corresponding to higher willingness to use PrEP.14 In other
periods, where numbers of sexual partners are lower (i.e., be-
ginning of a monogamous partnership), perceived risk of HIV
infection is lower, corresponding to lower willingness to use
PrEP.14 However, the oscillation of risk behaviors does not
fully account for all instances of PrEP discontinuation and
other factors (e.g., changes in insurance coverage and physician
access) also impact short- and long-term retention in care.10
To improve adherence and retention in PrEP care, various
clinical and behavioral interventions are being developed,7–10
involving counseling,15 education,16 mobile technologies,17
patient/peer navigation,18 and case management.19 Although
suboptimal adherence and retention in care can dampen the
individual-level benefits of PrEP, the optimal levels of ad-
herence and retention in PrEP care needed to maximize re-
ductions in HIV incidence at the population-level are not well
understood. Using data from a real-world PrEP program, we
adapted an existing ABM to evaluate the potential effective-
ness of interventions focused on improving adherence and
retention in care. We sought to determine optimal intervention




The Rhode Island Sexually Transmitted Diseases (STD)
Clinic is the only publicly funded STD clinic in the state.20 In
2013, the clinic began offering PrEP to patients with behavioral
indications according to recommendations from the United
States Public Health Service.21 We reviewed patient data from
2013 to 2017 for all MSM prescribed PrEP at our clinic in-
cluding demographic, behavioral, and laboratory data. Reten-
tion in care was evaluated based on attendance in quarterly
clinical visits, with data extracted on attendance at visits 3 and 6
months after initiation. Adherence was based on the self-
reported number of missed doses in the preceding 7 days at
each of these clinical visits, which previous studies have found
to be highly correlated with drug concentration levels in this
setting.22
Institutional Review Board approval and consent
This study was approved by the institutional review board
at the Miriam Hospital. This study also received a waiver of
consent.
Model setting
Clinic data were used to parameterize an ABM that sim-
ulated HIV transmission over a 5-year period among a virtual
population representing all MSM in Rhode Island. All model
parameters and processes have been described previously.5
The agents in the model were assigned specific demographic,
behavioral, and clinical characteristics (including probabili-
ties of adherence and retention in care) with distributions
informed by data on MSM who initiated PrEP at the Rhode
Island STD Clinic. Other local surveillance data and esti-
mates also informed this model (Table 1).
Model progression
The ABM simulated a dynamic population in a steady
state, where agents left the population at death or because of
aging at 65 years. Agents were replaced based on demo-
graphic, behavioral, and clinical attributes drawn stochas-
tically from the same distributions used to develop the base
population. The model progressed in discrete monthly time-
steps, during which agents were able to form and dissolve
sexual partnerships. At the beginning of each year, agents
were assigned target numbers of partners and sex acts for
that year drawn from local data.23 Agents were able to form
sexual partnerships with each other at a given time-step and
additional partnerships at future time-steps in a probabi-
listic fashion based on their target annual number of part-
ners. Partnerships were assigned a set duration at their
formation, allowing for a dynamic sexual network where
partnerships are formed and dissolved over time. All sim-
ulations were coded, tested, and calibrated in Python
(Version 2.7.13). All model outputs were analyzed in R
(Version 3.5.3).
HIV transmission
At model initialization, agents were assigned a sexual role
to determine their position during anal sex (receptive or in-
sertive). The probability of condom use within the partner-
ship was a function of the number of previous sexual acts
with a given partner, where condom use was most com-
mon in new partnerships.24 Condom-protected sex acts were
assumed to carry no risk. All condomless anal sex acts within
serodiscordant dyads were assumed to carry some risk of HIV
transmission, where the base estimates of per-act risk of HIV
transmission were set at 1.38% and 0.11% for receptive and
insertive anal sex, respectively.25 These probabilities were
scaled based on whether the HIV-positive partner within the
dyad was aware of their infection status, was on treatment,
and had achieved viral load suppression, and whether the
HIV-negative partner within the dyad was using PrEP. The
proportion of HIV-positive agents aware of their infection
status was estimated to be 82% and the proportion of HIV-
positive agents who had achieved viral load suppression was
set at 27%.26
















































In the base case scenario, agents using PrEP were retained
in care at 6 months after initiation with a probability of 60%
and were adherent (i.e., took four or more doses per week)
with a probability of 82%, based on observed clinic data.10
The impact of varying adherence and retention on the number
of HIV infections averted (NIA) in counterfactual scenarios
were then determined for the overall population of MSM, and
the population of MSM who had ever initiated PrEP. The first
scenario held adherence constant with a probability of 82%
while varying the proportion of agents retained in care from
60% to 88% (based on the increases predicted by a hypo-
thetical intervention that improves retention based on odds up
to 5.0). The second set of scenarios held retention in care
constant with a probability of 60% while varying the pro-
portion of agents with optimal adherence from 82% to 96%
(simulating a hypothetical intervention that improves ad-
herence with odds up to 5.0). NIAs for each counterfactual
scenario were calculated as the mean difference between the
cumulative number of infections in the base case and the
cumulative number of infections in the modeled scenario.
These estimates are also presented as percent change in the
cumulative number of infections.
Each scenario began in January 2013 and ended in De-
cember 2017. This 5-year period was selected as the time
horizon for all model scenarios as this represents the time
after which no agents who initiated PrEP at model initiali-
zation would be retained in care, assuming no further initi-
ation of other agents on PrEP. As described previously, the
ABM was calibrated to reproduce the observed HIV diag-
nosis and estimated prevalence trajectories in Rhode Island
from 2009 to 2013.27 Each of these scenarios was simulated
500 times and all runs were subject to a burn-in period (i.e., a
period in which transmission was simulated without PrEP) of
4 years before the initiation of the PrEP program. With all
outcome measures, we report 95% simulation intervals (SIs)
as measures of uncertainty.
Results
The model was based on the total population of MSM in
the state of Rhode Island (n = 23,815),28 with an estimated
4.1% prevalence of HIV infection.29 At model initialization,
20% of HIV-negative MSM were assumed to have ever ini-
tiated PrEP.10 In the base case scenario, there were an esti-
mated 173.1 new infections over 5 years (95% SI = 171.5–
174.7), including 29.1 new infections among the individuals
who had ever initiated PrEP (95% SI = 28.6–29.7).
Table 1. Key Parameter Values for an
Agent-Based Model (ABM) Assessing Pre-Exposure
Prophylaxis (PrEP) Implementation Among






















Sexual behavior and network
Preferred role in anal intercourse (%)
Exclusively insertive role 18.7
Exclusively receptive role 10.8
Either insertive or receptive role 70.5






10 or more partners 8.0








156 Acts or more 14.1
Probability of condom nonuse (%)
0 Previous encounters with sexual partner 44.3
1 Previous encounter with sexual partner 48.1
2–9 Previous encounters with sexual partner 51.4
10 or more previous encounters with sexual
partner
75.9
HIV transmission and treatment
Probability of HIV infection per act (%)
HIV-negative partner is in the insertive role in
anal intercourse
0.11
HIV-negative partner is in the receptive role in
anal intercourse
1.38
Continuum of care for HIV treatment (%)
People living with HIV infection aware of their
infection status
82.0






People living with HIV infection with viral
load suppression
45.0
Preexposure prophylaxis use (%)
Retention in clinical care
6 Months postinitiation 60.0
Medication adherence (%)
4–7 Doses per week 82.0
2–3 Doses per week 18.0















































Assuming constant levels of adherence (82%), interven-
tions focused on increasing retention in PrEP care had a
significant impact on the overall reduction in new HIV in-
fections among MSM. As retention in PrEP care increased
from 60% to 75% [intervention efficacy odds ratio
(OR) = 2.0], the number of new HIV infections among MSM
who had ever initiated PrEP (Fig. 1) decreased from 29.1
(95% SI = 28.6–29.7) to 26.2 (95% SI = 25.7–26.7), re-
presenting a reduction of 13.8% (95% SI = 12.2 = 15.3).
Maximum reductions were observed when retention in PrEP
care was 88% (equivalent to an intervention OR of 5.0),
which resulted in a 37.5% reduction in HIV incidence among
MSM who had ever initiated PrEP.
Assuming constant rates of retention in PrEP care (60%),
increasing the proportion of MSM with optimal adherence to
PrEP had little to no effect on the overall number of new HIV
infections among MSM over the simulation period. As ad-
herence increased from 82% to 92%, the number of new HIV
infections among MSM who had ever initiated PrEP re-
mained constant (Fig. 1), with 29.1 (95% SI = 28.6–29.7) and
29.7 (95% SI = 29.1–30.2) infections over 5 years in each
scenario, representing little or no change from the base case
scenario (2.4% reduction; 95% SI = -0.5 to 4.2).
In scenarios where adherence and retention in care were
jointly varied (Fig. 1), synergistic reductions in the number of
new HIV infections among MSM who had ever initiated
PrEP were not observed.
Discussion
This is among the first studies to evaluate the population-
level impact of potential interventions targeting adherence and
retention in PrEP care on HIV incidence among MSM. We
found that lower rates of retention in PrEP care and not ad-
herence alone led to increased HIV transmission. Retention in
PrEP care is tightly linked to adherence but focusing only on
adherence may overlook the importance of retention. In our
model, interventions that improved retention in PrEP care led
to greater reductions in HIV incidence compared with inter-
ventions that improved adherence alone. Although early
studies suggested that PrEP adherence may be a limiting step
during implementation, our previous work10 and this study
suggest that retention in PrEP care may be as or more im-
portant as efforts to promote adherence alone. In addition, we
determined the optimal effectiveness of an intervention tar-
geting retention in PrEP care to maximize reductions in HIV
incidence. These results will help guide PrEP implementation
and intervention development to achieve optimal outcomes
across the PrEP care continuum. Future models should ex-
plicitly incorporate race/ethnicity to identify the impacts of
these interventions on disparities in HIV incidence among key
populations (e.g., young black/African American MSM).
Retention in PrEP care is one of the least studied aspects of
the PrEP care continuum.4 Emerging data suggest that
retention in PrEP care is suboptimal across multiple popula-
tions.10 Reasons include individual-, social-, and structural-
level challenges including cost, stigma, risk perception, side
effects, and access to care.10,13 Of note, adherence and reten-
tion in PrEP care are inter-related. Individuals who are retained
in PrEP care are largely adherent to the medication.10 How-
ever, individuals who are not retained in PrEP care cannot be
adherent. Although adherence is needed for PrEP to be effec-
tive, retention in care is the critical step that undergirds, pre-
cedes, and promotes adherence. Of importance, individuals
retained in care may benefit from other HIV prevention ap-
proaches (e.g., routine HIV screening), even if they are sub-
optimally adherent to PrEP.
We find that enhancing retention in PrEP care could
achieve an estimated 40% reduction in HIV incidence with an
intervention efficacy of 5.0. After this point, population-level
changes in HIV incidence would be minimal. Interventions
focused on improving PrEP adherence alone had little to no
effect in our study. Previous interventions focused on reten-
tion in HIV care have demonstrated an effect of up to an
OR of 3.0.30 These retention in HIV care interventions have
focused on mobile health programs, case management,
peer/patient navigation, support services, and others.31 Given
this, achieving a PrEP intervention with an OR of 5.0 may be
optimistic, but suggests a possible ideal intervention goal.
This study is subject to several limitations. The model was
based on the state of Rhode Island and results may not be
generalizable to other settings. As with any model, some
assumptions were made. We assumed a higher estimate of
PrEP uptake than in reality, which was needed to fully
evaluate PrEP outcomes. However, every attempt was made
to otherwise use local data that reflected the current popula-
tion. Our findings have important implications for PrEP im-
plementation across the United States.
In conclusion, this is among the first studies to evaluate
interventions focused on improving adherence and retention
in PrEP care and effect on population-level HIV incidence.
Interventions that improved retention in PrEP care had the
greatest impact on reducing population-level HIV incidence,
but improvements plateaued at a given level. These results
FIG. 1. Estimated impact of a joint intervention improv-
ing adherence and retention in care among men who have
sex with men who use pre-exposure prophylaxis on HIV
incidence. Each tile in the chart notes a different combina-
tion of intervention efficacies for improving retention in care
(ORs from 1.0 to 2.0) and for improving adherence (ORs
from 1.0 to 2.0). Looking across the rows, HIV incidence is
reduced when retention in care is improved, but looking
down the columns, there is little or no difference when
adherence is improved on its own. OR, odds ratio.















































suggest that interventions targeting retention in care should
be a focus to achieve optimal PrEP continuum of care out-
comes. In addition, long-acting antiretroviral drug formula-
tions should be considered for populations that face
disproportionate barriers to adherence and retention in care
and could benefit from the longer periods of protection that
may be conferred by these modalities.32
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